Authors: Karen G Farrar University of Southern California , Los Angeles, CA, Duy Do Truveta, Inc , Bellevue, WA, Nina B Masters Truveta, Inc , Bellevue, WA, Brianna M Cartwright Truveta, Inc , Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred formulary option in July 2025, switching from anti-obesity tirzepatide surged from 0.6% to 9.7%, representing more than a 16-fold rise
Insulin resistance and hyper glycemia are established as factors that increase oxidative stress
Of the 19 subjects whose pretreatment cyanide levels were considered potentially lethal, 11 (58%) survived
Adjustments to the dosage may be required based on the subjects responses and study objectives